Signaturefd 13F: Adds $1.1M to Eli Lilly and (LLY) Stake
Key Points
- Signaturefd's stake in Eli Lilly increased by 961 shares, a 3.7% boost, in its latest 13F filing.
- Signaturefd held 27,035 $LLY shares at quarter end, up 3.69% from the prior quarter.
- As of October 27, 2026, Eli Lilly shares traded at about $1,279.16, slightly above the $1,273.46 closing price on the filing date.
- With this adjustment, Signaturefd holds 0.68% of its total portfolio in Eli Lilly, ranked 22nd among its holdings.
Since the filing, $LLY is up 0.5% to date (from the $1,273.46 close on Oct 23, 2026).
Get Eli Lilly and Company text alerts
We text you when insiders, Congress, analysts or big funds move on $LLY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Eli Lilly and Company alert may contain errors. Disclosures
On October 23, 2026, Signaturefd boosted its stake in Eli Lilly and Company (LLY) by 961 shares, bringing its total to 27,035 shares valued at approximately $31.3 million. This change was disclosed in the fund's latest Form 13F filing with the SEC.
LLY
Eli Lilly and Company
Signaturefd vs. the S&P 500
Hypothetical returns from Signaturefd's disclosed trades, not real profit or advice. How we model this.
Where Eli Lilly Fits in Signaturefd's Portfolio
Signaturefd's investment in Eli Lilly now makes up 0.68% of its total portfolio, ranked 22nd among its holdings. The increase of 961 shares represents a 3.7% boost in this position.
Other Institutional Activity in Eli Lilly
Several other institutional investors also adjusted their positions in Eli Lilly. True North Advisors added 1,108 shares, bringing its total to 4,217 shares worth about $4.9 million. Meanwhile, Midwest Trust grew its stake by 5,069 shares, ending with 73,312 shares valued at approximately $84.8 million. In contrast, Wilmington Savings Fund Society trimmed its holdings by 2,600 shares, reducing its total to 25,292 shares.
Eli Lilly and Company Stock Up 0.4%
Eli Lilly shares recently traded around $1,279.16 as of October 27, 2026, which is about 0.4% above the $1,273.46 closing price on the filing date. The stock is currently above its 50-day moving average by 7.8% and its 200-day average by 17.9%, indicating strong performance.
Recent Earnings
For the trailing twelve months, Eli Lilly reported revenue of approximately $79.7 billion and an earnings per share (EPS) of $29.79. The company is set to announce its next earnings results on October 29, 2026.
Dividend
Eli Lilly pays an annual dividend rate of $6.92, which translates to a yield of 0.54%. The payout ratio stands at 21.7%.
Insider Buying and Selling at Eli Lilly and Company
Insiders at Eli Lilly have been active, with General Counsel Anat Hakim selling 5,000 shares on August 7, 2026, at an average price of $1,190, totaling about $5.95 million. Officer Donald A. Zakrowski sold 2,000 shares on August 10, 2026, for about $2.37 million, while Officer Patrik Jonsson sold 6,500 shares on August 17, 2026, valued at approximately $7.64 million.
Analysts Set New Price Targets
On October 21, 2026, Leerink Partners maintained an Outperform rating on Eli Lilly with a price target of $1,316. JP Morgan and Morgan Stanley also maintained Overweight ratings with price targets of $1,500 and $1,430, respectively. The consensus recommendation for Eli Lilly is a buy, with a mean target price of approximately $1,331.55 from 30 analysts.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products globally. With a strong focus on healthcare, the company has a market cap of about $1.14 trillion and continues to expand its offerings in various therapeutic areas.
Bottom Line
Investors will be looking forward to Eli Lilly's upcoming earnings report on October 29, 2026, and further updates from institutional investors in their next 13F filings. Signaturefd's recent boost in its stake is part of a broader trend among funds adjusting their investments in this healthcare giant.
Related Filing Alerts
Source: Signaturefd's 13F filing on $LLY (Oct 23, 2026). 13F filings show holdings as of the end of the reporting quarter and may not reflect the fund's current position. Written by software, not financial advice. How we make alerts